Screener
Alto Neuroscience ANRO Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,294 | $9,974 |
| General and administrative | 6,844 | 5,702 |
| Total operating expenses | 27,138 | 15,676 |
| Loss from operations | (27,138) | (15,676) |
| Other income (expense): | ||
| Interest income | 1,561 | 1,827 |
| Interest expense | (545) | (598) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's total operating expenses?
- Alto Neuroscience (ANRO) reported total operating expenses of $27.14M in Q1 2026.
- How has Alto Neuroscience's total operating expenses changed year-over-year?
- Alto Neuroscience's total operating expenses increased by 73.1% year-over-year, from $15.68M to $27.14M.
- What is the long-term trend for Alto Neuroscience's total operating expenses?
- Over 2 years (2023 to 2025), Alto Neuroscience's total operating expenses has grown at a 32.5% compound annual growth rate (CAGR), from $37.81M to $66.36M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Alto Neuroscience's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude